CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients with Lymph-Node–Negative, Hormone-Responsive, HER2-Negative, T1-T2 Breast Cancer
Guiyun Sohn, Sei Hyun Ahn, Hee Jeong Kim, Byung-Ho Son, Jong Won Lee, Beom Seok Ko, Yura Lee, Sae Byul Lee, Seunghee Baek
Cancer Research and Treatment. 2016;48(4):1351-1362.   Published online 2016 April 6    DOI: https://doi.org/10.4143/crt.2015.444

Excel Download

Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients with Lymph-Node–Negative, Hormone-Responsive, HER2-Negative, T1-T2 Breast Cancer
Cancer Research and Treatment. 2016;48(4):1351-1362   Crossref logo
Link1 Link2 Link3

Survival outcome of combined GnRH agonist and tamoxifen is comparable to that of sequential adriamycin and cyclophosphamide chemotherapy plus tamoxifen in premenopausal early breast cancer patients
The Breast. 2017;32:S24   Crossref logo
Link1 Link2

Goserelin plus tamoxifen compared to chemotherapy followed by tamoxifen in premenopausal patients with early stage-, lymph node-negative breast cancer of luminal A subtype
The Breast. 2016;30:111-117   Crossref logo
Link1 Link2

Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404
Cancer Chemotherapy and Pharmacology. 2014;74(3):603-609   Crossref logo
Link1 Link2 Link3

Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen receptor-positive breast cancer patients. Very late results of the ‘gruppo di ricerca per la chemio-ormonoterapia adiuvante (GROCTA)’ 01-Trial in early breast cancer
Breast Cancer Research and Treatment. 2011;126(3):653-661   Crossref logo
Link1 Link2 Link3

Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy
Breast Cancer. 2013;22(1):71-78   Crossref logo
Link1 Link2 Link3

Evaluation of axillary lymph node status after axillary dissection in patients with SLN negative or single SLN positive T1 and T2 breast cancer
Annals of Medical Research. 2021;28(1):17   Crossref logo
Link1

EORTC study shows LHRH-agonist added to Tamoxifen improves premenopausal patients survival in metastatic breast cancer
European Journal of Cancer. 1997;33(1):6   Crossref logo
Link1 Link2

Menstruation recovery after chemotherapy and luteinizing hormone-releasing hormone agonist plus tamoxifen therapy for premenopausal patients with breast cancer
Surgery Today. 2010;41(1):48-53   Crossref logo
Link1 Link2 Link3

Adjuvant Surgical Oophorectomy Plus Tamoxifen in Premenopausal Women With Operable Hormone Receptor–Positive Breast Cancer: A Global Treatment Option
Clinical Breast Cancer. 2016;16(4):233-237   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.